Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Circulating Tumor Cells As a Surrogate Marker for Bone Marrow Minimal Residual Disease and an Adverse Prognostic Factor for Patients with Multiple Myelom

Stefanie Huhn, PhD, Mathias Hänel, MD, Thomas Hielscher, PhD, Uta Bertsch, MD, Hans Jürgen Salwender, Norma Peter, MD, Hartmut Kirchner, Helga Bernhard, MD, Martin Vogel, Ralf Angermund, Martin Goerner, MD, Katja C. Weisel, Jan Duering, Igor W Blau, Niels Weinhold, PhD, Hartmut Goldschmidt, MD

Blood (2017) 130 (Supplement 1): 4359.

https://doi.org/10.1182/blood.V130.Suppl_1.4359.4359

Published: 2017

Journal Articles

Bortezomib-Dexamethasone Alone or Plus Cyclophosphamide or Lenalidomide As Second-Line Treatment for Patients with Multiple Myeloma: Final Results From a Phase 2 Study

Meletios Athanasios Dimopoulos, MD, Meral Beksac, MD, Lotfi Benboubker, MD, PhD, Huw Roddie, MBChB, PhD, Nathalie Allietta, Esther Broer, Catherine Couturier, PharmD, Marie-Andrée Mazier, DESS, Ralf Angermund, MD, Thierry Facon, MD

Blood (2011) 118 (21): 1861.

https://doi.org/10.1182/blood.V118.21.1861.1861

Published: 2011

Journal Articles

Treatment of Indolent Non-Hodgkin’s Lymphoma in Germany - Results of a Representative Population-Based Survey.

Martin Dreyling, MD, Sebastian Fetscher, MD, P. Kornek, MD, Arnd Nusch, MD, Martin Kornacker, MD, Ralf Angermund, MD, Harold Pliskat, MD, Lenka Kellermann, Thomas Kegel, MD

Blood (2007) 110 (11): 1353.

https://doi.org/10.1182/blood.V110.11.1353.1353

Published: 2007

Journal Articles

Bortezomib Once Weekly Is Well Tolerated as Maintenance Therapy after Less Than a Complete Response to High-Dose Melphalan in Patients with Multiple Myeloma.

Stefan Knop, MD, Holger Hebart, MD, Volker Kunzmann, MD, Ralf Angermund, MD, Hermann Einsele, MD

Blood (2006) 108 (11): 5099.

https://doi.org/10.1182/blood.V108.11.5099.5099

Published: 2006

Journal Articles

Final Results of a Prospective, Non-Interventional Study on Bortezomib (Velcade®, VEL) in the Treatment of Multiple Myeloma (MM) in Office-Based Hematology Units (OBH).

Wolfgang Ulrich Knauf, MD, Burkhard Otremba, MD, Friedrich Overkamp, MD, Susanne Bammer, PhD, Ralf Angermund, MD

Blood (2006) 108 (11): 5109.

https://doi.org/10.1182/blood.V108.11.5109.5109

Published: 2006

Journal Articles

Uptake of New Therapeutics in the Treatment of Multiple Myeloma (MM) in Germany (GER) - Results from a Representative Multicentre Treatment Survey 2006.

Ralf Angermund, MD, W. Knauf, MD, M. Freund, MD, M. Nowrousian, MD, H. Einsele, MD, H. Goldschmidt, MD, W. Berdel, MD, W. Poenisch, MD, C. Straka, MD, L. Kellermann, H. Pliskat, PhD

Blood (2006) 108 (11): 5110.

https://doi.org/10.1182/blood.V108.11.5110.5110

Published: 2006

Journal Articles

Role of Bortezomib in the Treatment of Multiple Myeloma - First Results from a Representative Multicentre Treatment Survey in Germany (GER).

Ralf Angermund, W. Knauf, M. Freund, M. R. Nowrousian, H. Einsele, H. Goldschmidt, W. E. Berdel, W. Poenisch, C. Straka, L. Kellermann, S. Bammer

Blood (2005) 106 (11): 5156.

https://doi.org/10.1182/blood.V106.11.5156.5156

Published: 2005

NARROW

Circulating Tumor Cells As a Surrogate Marker for Bone Marrow Minimal Residual Disease and an Adverse Prognostic Factor for Patients with Multiple Myelom

Bortezomib-Dexamethasone Alone or Plus Cyclophosphamide or Lenalidomide As Second-Line Treatment for Patients with Multiple Myeloma: Final Results From a Phase 2 Study

Treatment of Indolent Non-Hodgkin’s Lymphoma in Germany - Results of a Representative Population-Based Survey.

Bortezomib Once Weekly Is Well Tolerated as Maintenance Therapy after Less Than a Complete Response to High-Dose Melphalan in Patients with Multiple Myeloma.

Final Results of a Prospective, Non-Interventional Study on Bortezomib (Velcade®, VEL) in the Treatment of Multiple Myeloma (MM) in Office-Based Hematology Units (OBH).

Uptake of New Therapeutics in the Treatment of Multiple Myeloma (MM) in Germany (GER) - Results from a Representative Multicentre Treatment Survey 2006.

Role of Bortezomib in the Treatment of Multiple Myeloma - First Results from a Representative Multicentre Treatment Survey in Germany (GER).

Email alerts

ASH Publications

American Society of Hematology

Circulating Tumor Cells As a Surrogate Marker for Bone Marrow Minimal Residual Disease and an Adverse Prognostic Factor for Patients with Multiple Myelom

Bortezomib-Dexamethasone Alone or Plus Cyclophosphamide or Lenalidomide As Second-Line Treatment for Patients with Multiple Myeloma: Final Results From a Phase 2 Study

Treatment of Indolent Non-Hodgkin’s Lymphoma in Germany - Results of a Representative Population-Based Survey.

Bortezomib Once Weekly Is Well Tolerated as Maintenance Therapy after Less Than a Complete Response to High-Dose Melphalan in Patients with Multiple Myeloma.

Final Results of a Prospective, Non-Interventional Study on Bortezomib (Velcade®, VEL) in the Treatment of Multiple Myeloma (MM) in Office-Based Hematology Units (OBH).

Uptake of New Therapeutics in the Treatment of Multiple Myeloma (MM) in Germany (GER) - Results from a Representative Multicentre Treatment Survey 2006.

Role of Bortezomib in the Treatment of Multiple Myeloma - First Results from a Representative Multicentre Treatment Survey in Germany (GER).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only